INTANGIBLE ASSETS

12 Months Ended

Dec. 31, 2024

5.	INTANGIBLE ASSETS

Intangible assets at December 31, 2024 and 2023 consist of the following:

	December 31, 2024						December 31, 2023
	(In thousands)
	Cost		Accumulated Amortization		Net		Cost		Accumulated Amortization		Net
Trademark and other intangible rights related to Nabi-HB	$	4,100	$	4,100	$	-	$	4,100	$	3,856	$	244
Internally developed software		559		99		460		210		9		201
Rights to intermediates		907		907		-		907		853		54
	$	5,566	$	5,106	$	460	$	5,217	$	4,718	$	499

Under the previous contract manufacturing agreement between ADMA and Biotest, intermediate by-products derived from the manufacture of ASCENIV were property of Biotest. As a result of the acquisition of certain assets from Biotest on June 6, 2017, ADMA obtained the right to these intermediate products as well as the intangible rights to Nabi-HB, which were amortized over a period of seven years. As of December 31, 2024, the Company’s intangible assets are comprised of several internally developed data intelligence and analytics programs at a cost of approximately $0.6 million which is being amortized over a period of four years.

Amortization expense related to the Company’s intangible assets for the years ended December 31, 2024, 2023 and 2022 was $0.4 million, $0.7 million and $0.7 million, respectively. Estimated aggregate future aggregate amortization expense is expected to be as follows (in thousands):

2025	$	140
2026	$	140
2027	$	130
2028	$	50